🔗 Share this article

An underground market for unlicensed weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations.

Investigational Treatment Acquiring Popularity Via Social Media

The experimental drug, which is still in research studies, is being promoted by social media influencers for its alleged fat-burning properties. Viewers are encouraged to contact these accounts directly for source information, while also receiving discount codes.

Active Commerce on Social Networks

Separately, a robust market exists on Telegram, where communities with numerous of members share comparison photos, injection guides and claims of next-day UK delivery. Vendors market the substance there before redirecting customers to other platforms for transactions.

Understanding The Experimental Drug

Retatrutide is an investigational injectable developed by US drugmaker Eli Lilly. The drug affects three gut hormones – GLP-1, GIP and glucagon. Early trials indicate it could assist patients lose up to 25% of their total weight. Referred to as the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Medical Professionals Voice Worries

Nevertheless, doctors and pharmacists have warned that the distribution of what remains an unapproved drug in the UK is worrisome and could lead to users injecting products of uncertain source.

Some experts stated the popularity for retatrutide could be connected to the increasing cost of licensed weight loss products such as Mounjaro.

Legal Status and Enforcement

Selling the unapproved drug on social media or Telegram is illegal in the UK, as it is an unlicensed drug that must not be promoted or distributed for personal consumption under the British medical regulations.

Several influencers attempt to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and supply can still violate medicines, marketing, and customer regulations, potentially leading to fines, legal action or prison.

Platform Reaction and Content Removal

According to the social media company, the service has taken down problematic material and banned associated keywords and query recommendations. The company stated it was committed to maintaining the service safe and investing in enhancing enforcement strategies.

Online Marketplace Operations

Research also discovered communities with up to 9,000 participants selling retatrutide using the platform's integrated discovery tool, which functions like a online catalog. Entering “retatrutide” immediately brings up channels with thousands of users, populated with photos of slimming results, glowing reviews and detailed instructions for mixing or administering at residence.

Within minutes of entering one community, a seller shared contact information, where the majority of transactions take place. The seller sent an guidebook and promised delivery within two days. When asked whether the product was genuine, one vendor responded: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. Not one asked about weight, medical conditions or previous experience.

Item Details and Costs

Within these communities, messages display black plastic parcels with Royal Mail stickers, stating to include new batches. One communication read: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, mixed at residence with purified liquid, or ready-to-use injectors typically priced at £160 for 20mg. When questioned how much time a injector should be used, vendors give conflicting responses ranging from a several days to “depends on your body”.

Service Oversight and Safety Actions

A representative for the messaging service said it actively moderated dangerous material on its service including material that encouraged the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are injecting materials they cannot confirm. Even if the research behind this drug is sound, these online versions may not contain what they advertise,” said a pharmacy expert, the director of pharmaceutical services at a pharmacy service.

A medical professional of an online medical service linked the surge in demand to current price rises for approved weight-loss medications such as Mounjaro. “With prices rising, individuals are using online platforms. But fake injections are extremely risky. You can’t be certain what’s contained or whether the conditions they were produced in was clean,” she said.

Her team has previously seen patients injured by self-injection from unconfirmed sources. “We recognize the frustration, but purchasing from messaging apps or WhatsApp is gambling with your health,” said Wyllie. “These materials could be impure or improperly measured.”

Manufacturer Statement

A representative from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any government authority anywhere in the world. “Therefore at this time no one can sell [it] for personal consumption,” they said, noting that any product “misleadingly claiming itself as a Lilly experimental substance not yet approved … may subject patients to possibly significant health risks”.